Frazier Co-Founders Topper And Heron Report 7.4% Stake In Phathom After Updating Filing
James Topper's 6,013,327 shares equal 7.4% of Phathom, the latest amendment to the Frazier group's ownership statement shows.
James Topper, who shares control of two Frazier Life Sciences funds with Patrick Heron, reports owning 6,013,327 shares of Phathom Pharmaceuticals, or 7.4% of the common stock, in an ownership amendment filed Monday. The filing updates addresses and holdings, and the event date is October 29, 2026.
How the 7.4% adds up
Topper's total includes 80,000 options he holds directly and shares held through Frazier Life Sciences IX and X. His percentage is figured on 81,291,520 shares outstanding as of October 27, plus those options.
Heron reports 5,901,756 shares, or 7.3%. Frazier Life Sciences IX alone holds 5,827,415 shares, or 7.2%, and Frazier Life Sciences X holds 59,403. Heron and Topper are the members of the general partner's management entity for those funds, so they share voting and investment power over those shares.
Frazier Life Sciences Public Fund holds 5,323,356 shares, or 6.5%. Its general partner is run by an investment committee of four, so no committee member is attributed ownership of those shares. Frazier Life Sciences XI holds 980,286 shares, or 1.2%, and XII holds 276,029, or 0.3%; each is governed by a three-person committee on the same basis.
Warrants outside the count
The tallies exclude warrants whose exercise is capped by ownership limits. The Public Fund holds warrants for 2,596,399 shares under a 9.99% cap, and XI holds 12,523 under the same cap.
A second set carries a 19.99% cap: 1,109,569 shares for the Public Fund, 10,376 for XI and 130,133 for XII.
A housekeeping amendment
Amendment No. 12 changes only two items: the reporting persons' business address, now in Palo Alto, California, and the ownership section. The funds are all Delaware entities, and Topper and Heron are U.S. citizens.
Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company selling gastrointestinal treatments. Its VOQUEZNA tablets and two VOQUEZNA pak products contain vonoprazan, an acid blocker approved for reflux disease and Helicobacter pylori infection. Its market value was $467 million in Monday trading.
The filing's share percentages rest on the 81,291,520 shares Phathom reported in its quarterly report filed October 29.